ArticleProceedings of the National Academy of Sciences of the United States of America2019
Pandemic fluoroquinolone resistant
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 67 citations in OpenAlex.
- Genomic surveillance of multidrug-resistant Enterobacterales in a long-term care facility in Northern Italy based on a point prevalence screening.Scientific reports · 2026Article
- Integrated conjugative elements drive the formation of pandemic clones of Escherichia coli with hybrid chromosomes.Molecular biology and evolution · 2026Article
- Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Whole-genome characterisation of high-risk ST131 and the emerging ST1193 UPEC lineages in Romanian patients with recurrent urinary tract infections.Frontiers in microbiology · 2026Article
- Exploration of the genomic diversity of third-generation cephalosporin-resistantMicrobial genomics · 2026Article
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Comparative genomic and phenotypic analysis of Escherichia coli ST1193 and ST131 from urinary and bloodstream infections: insights into resistance, virulence, and divergent strategies.BMC infectious diseases · 2025Article
- Changes in Antimicrobial Resistance in Pediatric Urinary Pathogens Before, During, and After the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2025Article
- Emergence of a carbapenem-resistant atypical uropathogenic Escherichia coli clone as an increasing cause of urinary tract infection.Nature communications · 2025Article
- Genomic diversity of uropathogenic Escherichia coli in clinical isolates from six latin american countries, 2018-2023.Revista peruana de medicina experimental y salud publica · 2025Article
- Lineage-specific variation in frequency and hotspots of recombination in invasive Escherichia coli.BMC genomics · 2025Article
- Unraveling the Resistome, Virulome, and Pathogenicity ofInternational journal of microbiology · 2025Article
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- Non-Canonical Aspects of Antibiotics and Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Gut residentmedRxiv : the preprint server for health sciences · 2024Article
- Multidrug resistance plasmids commonly reprogram the expression of metabolic genes inmSystems · 2024Article
- Review
- The complete genome sequence of five pre-2013 Escherichia coli sequence type (ST)1193 strains reveals insights into an emerging pathogen.Access microbiology · 2024Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Global growth in antibiotic resistance is a major social problem. A high level of resistance to fluoroquinolones requires the concurrent presence of at least 3 mutations in the target proteins-2 in DNA gyrase (GyrA) and 1 in topoisomerase IV (ParC), which occur in a stepwise manner. In the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.